Guerbet S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GUERF research report →
Companywww.guerbet.com
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services.
- CEO
- David Hale
- IPO
- 2017
- Employees
- 2,839
- HQ
- Villepinte, FR
Price Chart
Valuation
- Market Cap
- $281.03M
- P/E
- -1.13
- P/S
- 0.15
- P/B
- 0.46
- EV/EBITDA
- 7.92
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 23.40%
- Op Margin
- 0.17%
- Net Margin
- -13.78%
- ROE
- -33.69%
- ROIC
- 0.19%
Growth & Income
- Revenue
- $841.09M · 5.71%
- Net Income
- $16.08M · -32.61%
- EPS
- $1.28 · -32.63%
- Op Income
- $42.82M
- FCF YoY
- 207.76%
Performance & Tape
- 52W High
- $58.35
- 52W Low
- $22.25
- 50D MA
- $58.35
- 200D MA
- $58.35
- Beta
- 0.69
- Avg Volume
- 0
Get TickerSpark's AI analysis on GUERF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GUERF Coverage
We haven't published any research on GUERF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GUERF Report →